Natera has begun the subject enrolment in the randomised Phase III SAGITTARIUS clinical trial designed to assess the ...

The study aims to enroll approximately 700-900 stage III and high-risk stage II colon cancer patients following surgical resection. Signatera-positive patients will be randomized to receive either ...